Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 1-11

  Shen, Chuanlai ^a   Cheng, Kai ^a   Miao, Shenwei ^a   Wang, Wei ^a   He, Yong ^a   Meng, Fanyan ^a   Zhang, Jianqiong ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Active immunotherapy; Artificial antigen presenting cells (aAPCs); CTL response; MHC tetramer

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LATEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DRUG EFFICACY; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TREATMENT RESPONSE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; ARTIFICIAL CELLS; CELL LINE, TUMOR; CYTOKINES; MALE; MELANOMA; MEMBRANE PROTEINS; MICE; MICROSPHERES; NEOPLASMS; PEPTIDE FRAGMENTS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84874357246     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.01.003     Document Type: Article

References (29)

1. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
2. Janikashvili N., Larmonier N., Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010, 2:57-68.
3. Rodrigues C.M., Matias B.F., Murta E.F., Michelin M.A. The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. Clin Med Insights Oncol 2011, 5:107-115.
4. Turtle C.J., Riddell S.R. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J 2010, 16:374-381.
5. + T cells restricted by prevalent HLA-DR alleles. Int Immunol 2010, 22:863-873.
6. Steenblock E.R., Wrzesinski S.H., Flavell R.A., Fahmy T.M. Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. Expert Opin Biol Ther 2009, 9:451-464.
7. Mao H., Geng Z., Liu W., Sun H., Huang W. Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells. J Immunother 2008, 31:487-490.
8. Rudolf D., Silberzahn T., Walter S., Maurer D., Engelhard J., Wernet D., et al. Potent costimulation of human CD8T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother 2008, 57:175-183.
9. Durai M., Krueger C., Ye Z., Cheng L., Mackensen A., Oelke M., et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 2009, 58:209-220.
10. Lu X., Jiang X., Liu R., Zhang S., Liang Z. In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells. Cancer Immunol Immunother 2009, 58:629-638.
11. Chiu Y.L., Schneck J.P., Oelke M. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL. J Vis Exp 2011, 5. 10.3791/2801.
12. + T cell-targeted antigen-presenting cells elicit protective antitumor responses. Cancer Res 2008, 68:3010-3018.
13. Ugel S., Zoso A., De Santo C., Li Y., Marigo I., Zanovello P., et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res 2009, 69:9376-9384.
14. Shen C., Chang C.C., Zhang J., Guo W., Xia L., Meng F., et al. Structural and functional characterization of peptide-beta2m fused HLA-A2/MART1(27-35) complexes. Biochem Biophys Res Commun 2006, 342:57-65.
15. Meng F., Shen C., He Y., Miao F., Zhang J. Cloning and expression of three peptide-linked beta2-microglobulin molecules in Escherichia coli with an isocaudamer technique. Biotechnol Lett 2009, 31:831-836.
16. Shen C., He Y., Meng F., Cheng K., Zhang D., Miao F., et al. Characterization of MHC/peptide complexes refolded by a one-step ion-exchange chromatography. J Immunol Methods 2011, 369:81-90.
17. Shen C., Zhang J., Xia L., Meng F., Xie W. Induction of tumor antigen-specific cytotoxic T cell responses in naive mice by latex microspheres-based artificial antigen-presenting cell constructs. Cell Immunol 2007, 247:28-35.
18. Shen C., He Y., Cheng K., Zhang D., Miao S., Zhang A., et al. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation. Immunol Lett 2011, 138:144-155.
19. Tan R., Xu X., Ogg G.S., Hansasuta P., Dong T., Rostron T., et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999, 93:1506-1510.
20. Mitchell M.S., Darrah D., Yeung D., Halpern S., Wallace A., Voland J., et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002, 20:1075-1086.
21. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
22. Economou J.S., Belldegrun A.S., Glaspy J., Toloza E.M., Figlin R., Hobbs J., et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. J Clin Invest 1996, 97:515-521.
23. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000, 192:1637-1644.
24. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R., et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 2003, 170:2161-2169.
25. + cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007, 179:4910-4918.
26. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186:47-55.
27. Goldberg J., Shrikant P., Mescher M.F. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003, 170:228-235.
28. Mitchell M.S., Kan-Mitchell J., Morrow P.R., Darrah D., Jones V.E., Mescher M.F. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004, 10:76-83.
29. Zhao H., Saatchi K., Hafeli U.O. Preparation of biodegradable magnetic microspheres with poly(lactic acid)-coated magnetite. J Magn Magn Mater 2009, 321:1356-1363.